title: Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.
abstract: Bromovinyldeoxyuridine is a potent and safe antiherpes compound that in combination with a placebo treatment promoted the partial and complete healing of herpetic epithelial disease in 22 patients in average times of 4-6 days and 8.5 days respectively. However, when BVDU was combined with 1.5 X 10(6) IU of recombinant a 2C interferon, partial and complete healing times for keratitis in 19 patients were reduced to 2-6 days and 4-6 days respectively. No toxic effects of the medications were observed in any patient.
authors.affiliation: Royal Dutch Eye Clinic, Utrecht, The Netherlands.
authors.forename: O P
authors.initials: OP
authors.lastname: van Bijsterveld
authors.forename: P J
authors.initials: PJ
authors.lastname: Meurs
authors.forename: E
authors.initials: E
authors.lastname: de Clercq
authors.forename: P C
authors.initials: PC
authors.lastname: Maudgal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007635:Keratitis, Dendritic / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; C020235:brivudine; D001973:Bromodeoxyuridine